MedTrace Logo

A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3111 in Healthy Adults

NCT04238975 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 213

Last updated 2020-01-23

No results posted yet for this study

Summary

The purpose of this study is to evaluate safety and efficacy (immunogenicity) of a single dose of GC3111 versus Boostrix® vaccine among healthy adults in 19-64 years of age.

Conditions

Interventions

BIOLOGICAL

GC3111 vaccine

0.5mL, Intramuscular

BIOLOGICAL

Boostrix® vaccine

0.5mL, Intramuscular

Sponsors & Collaborators

  • Green Cross Corporation

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-10-14
Primary Completion
2021-02-28
Completion
2021-05-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04238975 on ClinicalTrials.gov